Cargando…

Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

Improvements in survival of patients with breast cancer have been attributed to the development of agents that target key components of dysregulated pathways involved in oncogenesis and progression of breast cancer. Aberrant mammalian target of rapamycin (mTOR) activation has been implicated in onco...

Descripción completa

Detalles Bibliográficos
Autor principal: Yardley, Denise A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579426/
https://www.ncbi.nlm.nih.gov/pubmed/23492649
http://dx.doi.org/10.4137/BCBCR.S10071